SOHO 2026 | Elritercept shows dual hemoglobin and platelet response in MF: insights from the RESTORE trial

So I think what we are learning about this drug is that it seems to reset the myelofibrosis bone marrow microenvironment. So clearly the activity on the TGF-beta downstream and particularly active in A and B seems to rebalance the relationship between the stem cells and the microenvironment. And that seems to have an effect in terms of not just hemoglobin improvement, but also platelets, which I think is very interesting because we haven’t seen many drugs that are working on both. So we have obviously drugs such as the hypo agonist that works on the erythroid component increasing the hemoglobin level but we haven’t seen a cross response on platelets and megakaryocytes and what RESTORE showed us was that there is quite often that dual response so anemia clearly is a unmet need and there is potential of this drug to help these patients. But also it’s very interesting how the thrombocytopenia, which is probably even more complex, a problem related to myelofibrosis patients, might respond and get better when patients are exposed to this drug. And I think it’s interesting that this is a population of patients previously pre-treated with ruxolitinib for at least eight weeks prior to recruitment. They might have been anemic to start, or they might develop anemia, as a number of patients do and they do have a response to the drug which I think is quite is quite helpful and also we seem to see you know some benefit in terms of a little burden reduction so there is potentially some disease modification going on with this drug which we need to monitor for a little bit longer to understand what the impact and the implications on the disease progression.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.